Exenatide: a new promising antidiabetic agent - Wikidata - awgldk - TriplyDB

Exenatide: a new promising antidiabetic agent

Exenatide: a new promising antidiabetic agent

http://www.wikidata.org/entity/Q40964981

about

Preclinical safety evaluation of submicronized sildenafil citrate nebulization solution in small experimental animals.Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.

P2860

Q40527687-5FE97266-A716-45DC-8EFF-50C16412349B Q51322701-DF901C63-9800-415B-B059-4A02632F8677

P2860

Exenatide: a new promising antidiabetic agent

http://www.wikidata.org/entity/Q40964981

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Exenatide: a new promising antidiabetic agent

@en

type

label

Exenatide: a new promising antidiabetic agent

@en

prefLabel

Exenatide: a new promising antidiabetic agent

@en

P1433

Q40964981-E3624FEB-9F64-4581-9CC5-EFE904AB0A5E

P1476

Q40964981-F16F4A1E-99E0-4714-A60E-33FADAC66A54

P2093

Q40964981-74411C6C-FC9E-433F-892E-93FD9D307BDA

P2860

Q40964981-087C7CF6-FE92-4AAD-8383-722E4F875F34

Q40964981-0BF3D41F-C8BB-45DD-B03C-BE542D9E7083

Q40964981-10839235-48D2-4468-A4D3-AEE54F4CB922

Q40964981-1699306C-A35D-4883-96FB-1A23B85EBC37

Q40964981-16D1C72A-DCB5-4EBA-86A7-DE34A59CE56C

Q40964981-19976CC0-AD6D-49D4-B49B-B4AA547312D8

Q40964981-227FB556-0A7C-4620-90F3-8F542E9518BD

Q40964981-231AEDA8-DBDD-490E-B726-B7CD86B8030B

Q40964981-2547DB74-BDEB-4524-B354-B689FB9D1A1F

Q40964981-30D74D40-2343-488B-ADEF-AA56AC10B80C

P304

Q40964981-E3A463DA-A4A8-457B-87E7-CCEBE43928C8

P31

Q40964981-F47C6D6E-B923-4171-8F8A-64C3533D50F5

P356

Q40964981-426335C4-6BFD-4F92-A618-70B48595B9B2

P433

Q40964981-631746F2-83DD-449F-8093-ECE35CA7BFB8

P478

Q40964981-D02E27DD-A412-4966-B1FB-041972EA9ECE

P577

Q40964981-E534362E-7DDD-4BF9-989E-9B9513594210

P698

Q40964981-6A35F978-A605-4046-974A-5BCF7F4A8AAD

P932

Q40964981-3BC8FA18-990E-4906-B659-19A595958FCC

P356

0250-474X.62228

P1433

Indian Journal of Pharmaceutical Sciences

P1476

Exenatide: a new promising antidiabetic agent

@en

P2093

C K Chakraborti

http://www.w3.org/2001/XMLSchema#string

P2860

Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus

Mechanisms of action of glucagon-like peptide 1 in the pancreas

Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.

New frontiers in the management of type 2 diabetes

Therapies for diabetes: pramlintide and exenatide

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.

Safety and adverse effects associated with GLP-1 analogues.

P304

1-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0250-474X.62228

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20582183

http://www.w3.org/2001/XMLSchema#string

P932

2883206

http://www.w3.org/2001/XMLSchema#string